Sign In
Buy CERO
$0.0120
-0.0009 (-6.98%)
At Close: Jun 03, 2026
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
08:15am, Monday, 11'th May 2026
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
08:15am, Tuesday, 14'th Apr 2026
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
08:15am, Monday, 30'th Mar 2026
Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
CERo Therapeutics Provides Shareholder Update
08:15am, Wednesday, 11'th Mar 2026
Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead inve
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
08:00am, Tuesday, 17'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing n
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on Febru
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, In
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
08:00am, Wednesday, 17'th Dec 2025
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1
CERo Therapeutics Announces Trading on OTCQB Market
07:30am, Tuesday, 02'nd Dec 2025
Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company�
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
08:00am, Wednesday, 05'th Nov 2025
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuin
Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CE
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
07:22pm, Wednesday, 29'th Oct 2025
Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Mar
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
08:15am, Tuesday, 21'st Oct 2025
Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdin
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
08:30am, Wednesday, 15'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announce
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
08:30am, Monday, 13'th Oct 2025
Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval
